News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
22,780 Results
Type
Article (1053)
Company Profile (2)
Press Release (21725)
Section
Business (11470)
Career Advice (49)
Deals (1447)
Drug Development (1833)
FDA (351)
Job Trends (454)
News (14454)
Policy (608)
Tag
Academia (28)
Accelerated approval (1)
Allergies (13)
Alliances (674)
ALS (1)
Alzheimer's disease (19)
Antibody-drug conjugate (ADC) (4)
Approvals (364)
Artificial intelligence (3)
Autoimmune disease (3)
Bankruptcy (10)
Best Places to Work (374)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (7)
Brain cancer (2)
Breast cancer (18)
Cancer (114)
Cardiovascular disease (17)
Career advice (31)
Career pathing (1)
CAR-T (7)
Cell therapy (21)
Clinical research (1713)
Collaboration (17)
Compensation (12)
Complete response letters (3)
COVID-19 (38)
CRISPR (3)
C-suite (1)
Cystic fibrosis (6)
Data (186)
Depression (4)
Diabetes (8)
Diagnostics (204)
Digital health (1)
Drug discovery (4)
Drug pricing (1)
Duchenne muscular dystrophy (5)
Earnings (11226)
Editorial (1)
Events (1919)
Executive appointments (4)
FDA (508)
Funding (10)
Gene editing (4)
Generative AI (1)
Gene therapy (13)
GLP-1 (16)
Government (49)
Grass and pollen (2)
Guidances (119)
Healthcare (539)
HIV (3)
IgA nephropathy (2)
Immunology and inflammation (4)
Immuno-oncology (1)
Indications (4)
Infectious disease (41)
Inflammatory bowel disease (1)
Influenza (3)
Intellectual property (5)
Interviews (10)
IPO (1100)
Job creations (103)
Job search strategy (30)
JPM (1)
Labor market (1)
Layoffs (12)
Legal (157)
Liver cancer (2)
Lung cancer (19)
Lymphoma (14)
Manufacturing (7)
MASH (7)
Medical device (532)
Medtech (536)
Mergers & acquisitions (351)
Metabolic disorders (20)
Multiple sclerosis (5)
Neurodegenerative disease (1)
Neuropsychiatric disorders (2)
Neuroscience (41)
NextGen: Class of 2026 (117)
Non-profit (45)
Obesity (5)
Opinion (1)
Ovarian cancer (3)
Pain (6)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (4)
Patient recruitment (4)
Peanut (3)
People (614)
Pharmacy benefit managers (1)
Phase 1 (421)
Phase 2 (692)
Phase 3 (686)
Pipeline (530)
Postmarket research (73)
Preclinical (122)
Prostate cancer (2)
Radiopharmaceuticals (11)
Rare diseases (22)
Real estate (81)
Regulatory (457)
Reports (3)
Research institute (25)
Resumes & cover letters (10)
Rett syndrome (1)
RSV (1)
Schizophrenia (4)
Series B (1)
Special edition (1)
Spinal muscular atrophy (1)
Startups (57)
Stomach cancer (1)
Vaccines (15)
Weight loss (4)
Women's health (1)
Worklife (1)
Date
Last 7 days (28)
Last 30 days (84)
Last 365 days (1223)
2026 (107)
2025 (1232)
2024 (1373)
2023 (1578)
2022 (1901)
2021 (1926)
2020 (1494)
2019 (1036)
2018 (871)
2017 (676)
2016 (361)
2015 (588)
2014 (393)
2013 (6234)
2012 (311)
2011 (358)
2010 (416)
Location
Africa (15)
Alabama (4)
Arizona (10)
Asia (1417)
Australia (157)
California (426)
Canada (150)
China (31)
Colorado (27)
Connecticut (27)
Delaware (12)
Europe (3252)
Florida (69)
Georgia (19)
Illinois (26)
India (2)
Indiana (19)
Japan (9)
Kansas (1)
Kentucky (2)
Louisiana (6)
Maine (4)
Maryland (57)
Massachusetts (252)
Michigan (15)
Minnesota (24)
Missouri (3)
Montana (1)
Nevada (3)
New Hampshire (4)
New Jersey (143)
New York (113)
North Carolina (66)
Northern California (201)
Ohio (7)
Pennsylvania (93)
South America (36)
South Carolina (1)
Southern California (184)
Tennessee (4)
Texas (41)
United States (1522)
Utah (22)
Virginia (2)
Washington State (38)
Wisconsin (5)
22,780 Results for "143".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
·
7 min read
Press Releases
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
·
8 min read
Layoffs
Genentech Lays Off 143 Employees in South San Francisco Reshuffle
The downsizing comes after a year of workforce cuts and reorganization for Roche’s subsidiary.
June 11, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
July 9, 2025
·
11 min read
Press Releases
Analgesics Market Size to Exceed USD 143.42 Billion by 2034 Rising Chronic Pain and Advancements in Pain Relief Treatments
July 10, 2025
·
1 min read
Press Releases
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
February 25, 2025
·
5 min read
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management.
May 15, 2024
·
2 min read
Drug Development
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Ultragenyx Pharmaceutical Inc. today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI).
April 30, 2024
·
8 min read
Press Releases
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
October 7, 2024
·
6 min read
Press Releases
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
September 27, 2024
·
7 min read
1 of 2,278
Next
